ArticlePancreas2025
Chymotrypsin B2 (CTRB2) Deletion Variant Induces Endoplasmic Reticulum Stress but does not Increase Risk for Chronic Pancreatitis.
Article in Pancreas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesCTRB2-del, a commonly occurring loss-of-function deletion variant in the CTRB2 gene encoding chymotrypsinogen B2 was shown to induce endoplasmic reticulum (ER) stress and increase risk for pancreatic cancer but not for chronic pancreatitis (CP). Since other digestive enzyme variants that cause misfolding and induce ER stress are strong risk factors for CP, the lack of association between CP and the CTRB2-del variant is surprising. The aim of the present study was to re-examine the biochemical and clinical characteristics of the CTRB2-del variant.
methodsWe performed experiments with AR42J cells transduced with adenoviral vectors and investigated disease association in Hungarian and German cohorts of CP cases.
resultsWe found that the CTRB2-del protein was not secreted from AR42J cells but accumulated inside and induced significant ER stress. Curiously, epitope tagging CTRB2-del with a polyhistidine tail abolished its capacity to elicit ER stress even though the tagged construct remained defective in secretion and was retained intracellularly. Human genetic studies demonstrated similar carrier frequency of the CTRB2-del variant in CP cases and controls.
conclusionsWe replicated the ER-stress causing effect of the CTRB2-del variant and confirmed the lack of association with CP. The observations also revealed that epitope-tagging may alter the cellular effects of the CTRB2-del protein. The lack of association between ER stress and CP risk in carriers of the CTRB2-del variant raises the possibility that ER stress is a marker of digestive enzyme misfolding but does not drive CP onset and/or progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.